Compare AbbVie Inc (ABBV) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Anheuser-Busch Inbev SA — how do they compare? AbbVie Inc trades at $253.86 (market cap $449.91B), while Anheuser-Busch Inbev SA trades at $79.5 (market cap $155.34B). The key difference: AbbVie Inc is far larger — about 2.9× Anheuser-Busch Inbev SA's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | BUD | |
|---|---|---|
Market Cap | $449.91B | $155.34B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $85.09 |
52-Week Low | $184.85 | $57.10 |
Enterprise Value | $513.38B | $216.53B |
Dividend Yield | 2.72% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
BUD trades at $79.74, down 1.95% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, maintains healthy profit margins (net income margin 11.9%), and shows improving cash flow trends. Recent news highlights premiumization strategies and digital expansion efforts to drive growth amid changing consumer preferences in the beverage-alcohol industry.
The outlook remains positive with analyst consensus pointing to 13% upside to the $90.08 price target. Key opportunities include continued earnings momentum and dividend yield support, while risks involve alcohol consumption trends and competitive pressures. The stock presents a compelling value proposition for investors seeking stable returns with moderate growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
